Clinical Control News Today

<p>Peptide receptor radionuclide therapy (PRRT) is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in the February issue of <em>The Journal of Nuclear Medicine</em>. In the largest study to date of metastatic insulinoma patients treated with PRRT, more than 80 percent of patients had long-lasting symptom control, and nearly 60 percent were able to reduce the use of other drugs to treat the disease.</p>